» Articles » PMID: 32093341

Network-Based Genetic Profiling Reveals Cellular Pathway Differences Between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma

Overview
Publisher MDPI
Date 2020 Feb 26
PMID 32093341
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular mechanisms underlying the pathogenesis and progression of malignant thyroid cancers, such as follicular thyroid carcinomas (FTCs), and how these differ from benign thyroid lesions, are poorly understood. In this study, we employed network-based integrative analyses of FTC and benign follicular thyroid adenoma (FTA) lesion transcriptomes to identify key genes and pathways that differ between them. We first analysed a microarray gene expression dataset (Gene Expression Omnibus GSE82208, n = 52) obtained from FTC and FTA tissues to identify differentially expressed genes (DEGs). Pathway analyses of these DEGs were then performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) resources to identify potentially important pathways, and protein-protein interactions (PPIs) were examined to identify pathway hub genes. Our data analysis identified 598 DEGs, 133 genes with higher and 465 genes with lower expression in FTCs. We identified four significant pathways (one carbon pool by folate, p53 signalling, progesterone-mediated oocyte maturation signalling, and cell cycle pathways) connected to DEGs with high FTC expression; eight pathways were connected to DEGs with lower relative FTC expression. Ten GO groups were significantly connected with FTC-high expression DEGs and 80 with low-FTC expression DEGs. PPI analysis then identified 12 potential hub genes based on degree and betweenness centrality; namely, TOP2A, JUN, EGFR, CDK1, FOS, CDKN3, EZH2, TYMS, PBK, CDH1, UBE2C, and CCNB2. Moreover, transcription factors (TFs) were identified that may underlie gene expression differences observed between FTC and FTA, including FOXC1, GATA2, YY1, FOXL1, E2F1, NFIC, SRF, TFAP2A, HINFP, and CREB1. We also identified microRNA (miRNAs) that may also affect transcript levels of DEGs; these included hsa-mir-335-5p, -26b-5p, -124-3p, -16-5p, -192-5p, -1-3p, -17-5p, -92a-3p, -215-5p, and -20a-5p. Thus, our study identified DEGs, molecular pathways, TFs, and miRNAs that reflect molecular mechanisms that differ between FTC and benign FTA. Given the general similarities of these lesions and common tissue origin, some of these differences may reflect malignant progression potential, and include useful candidate biomarkers for FTC and identifying factors important for FTC pathogenesis.

Citing Articles

Identification of Biomarkers and Molecular Pathways Implicated in Smoking and COVID-19 Associated Lung Cancer Using Bioinformatics and Machine Learning Approaches.

Hossain M, Rahman M, Bhuiyan T, Moni M Int J Environ Res Public Health. 2024; 21(11).

PMID: 39595659 PMC: 11593889. DOI: 10.3390/ijerph21111392.


Homeobox and Polycomb target gene methylation in human solid tumors.

Blanchett R, Lau K, Pfeifer G Sci Rep. 2024; 14(1):13912.

PMID: 38886487 PMC: 11183203. DOI: 10.1038/s41598-024-64569-5.


Contribution of FOS in neutrophils to venous thromboembolism via miR-144 based on bioinformatic prediction and validation.

Wang P, Zheng L, Qi X, Wang H, Zhang R, Song L J Cell Mol Med. 2024; 28(11):e18370.

PMID: 38818568 PMC: 11140234. DOI: 10.1111/jcmm.18370.


Assessment of causal association between differentiated thyroid cancer and disordered serum lipid profile: a Mendelian randomization study.

Ma Q, Li Y, An L, Guo L, Liu X Front Endocrinol (Lausanne). 2024; 14:1291445.

PMID: 38189054 PMC: 10771623. DOI: 10.3389/fendo.2023.1291445.


Role of hypermethylated SLC5A8 in follicular thyroid cancer diagnosis and prognosis prediction.

Yang Y, Liao C, Yang Q, Li Y, Tang Y, Xu B World J Surg Oncol. 2023; 21(1):367.

PMID: 38007446 PMC: 10675931. DOI: 10.1186/s12957-023-03240-1.


References
1.
Smyth G, Michaud J, Scott H . Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005; 21(9):2067-75. DOI: 10.1093/bioinformatics/bti270. View

2.
Xu H, Moni M, Lio P . Network regularised Cox regression and multiplex network models to predict disease comorbidities and survival of cancer. Comput Biol Chem. 2015; 59 Pt B:15-31. DOI: 10.1016/j.compbiolchem.2015.08.010. View

3.
Moni M, Lio P . Genetic Profiling and Comorbidities of Zika Infection. J Infect Dis. 2017; 216(6):703-712. DOI: 10.1093/infdis/jix327. View

4.
Masudo K, Suganuma N, Nakayama H, Oshima T, Rino Y, Iwasaki H . EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer. In Vivo. 2017; 32(1):25-31. PMC: 5892628. DOI: 10.21873/invivo.11200. View

5.
Liu Z, Liang G, Tan L, Su A, Jiang W, Gong C . High-efficient Screening Method for Identification of Key Genes in Breast Cancer Through Microarray and Bioinformatics. Anticancer Res. 2017; 37(8):4329-4335. DOI: 10.21873/anticanres.11826. View